Regeneron to highlight advances at asco with phase 3 adjuvant libtayo® (cemiplimab) cscc updates and promising early blood cancer data with linvoseltamab combination

18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies
REGN Ratings Summary
REGN Quant Ranking